1. Home
  2. NGNE vs PSNYW Comparison

NGNE vs PSNYW Comparison

Compare NGNE & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$17.20

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

N/A

Current Price

$2.95

Market Cap

290.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
PSNYW
Founded
2003
2017
Country
Sweden
Employees
N/A
2547
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
290.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
PSNYW
Price
$17.20
$2.95
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$40.14
N/A
AVG Volume (30 Days)
92.0K
5.1K
Earning Date
01-01-0001
03-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,034,261,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$79.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$0.13
52 Week High
$37.27
$7.50

Technical Indicators

Market Signals
Indicator
NGNE
PSNYW
Relative Strength Index (RSI) 43.48 43.87
Support Level $16.78 $2.75
Resistance Level $17.93 $3.00
Average True Range (ATR) 1.29 0.26
MACD 0.04 0.04
Stochastic Oscillator 31.24 59.98

Price Performance

Historical Comparison
NGNE
PSNYW

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Share on Social Networks: